Lenograstim

Lenograstim
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code L03AA10
UNII 6WS4C399GB Y
Chemical data
Formula  ?
 N(what is this?)  (verify)

Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as a immunostimulator.[1] It is developed by Ligand Pharmaceuticals (LGND) under the brand name Graslopin.

Lenograstim has been investigated as a possible adjunctive treatment for severe sepsis and found to be ineffective.[2]

References

  1. ^ Amadori S, Suciu S, Jehn U et al. (2005). "Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study". Blood 106 (1): 27–34. doi:10.1182/blood-2004-09-3728. PMC 1895135. PMID 15761020. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1895135. 
  2. ^ Stephens DP, Thomas JH, Higgins A et al. (2008). "Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock". Crit Care Med 36 (2): 448–454. doi:10.1097/01.CCM.0B013E318161E480. PMID 18216600. 
Endogenous
Other protein/peptide
Other
Exogenous

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)